Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
Page 1 of 1